Drugs / NT0102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01835548 | Jul 2013 → Jul 2014 | attention deficit-hyperactivity disorder | Neos Therapeutics, Inc | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NT0102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01835548 ↗ |
| Route | Oral | “Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.” NCT01835548 ↗ |